vx-770 and Substance-Withdrawal-Syndrome

vx-770 has been researched along with Substance-Withdrawal-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for vx-770 and Substance-Withdrawal-Syndrome

ArticleYear
Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2018, Volume: 17, Issue:2

    Ivacaftor use can lead to dramatic health improvements in cystic fibrosis (CF) patients with gating mutations. Here, we report five instances of dramatic clinical decline following withdrawal of ivacaftor in three individuals with the G551D-CFTR mutation. In each case, the patient's lung function and symptoms rapidly deteriorated after cessation of treatment. Awareness of this phenomenon should inform both clinical practices as well as the design of future clinical trials of highly active CFTR modulators.

    Topics: Adult; Aminophenols; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Forced Expiratory Volume; Humans; Male; Mutation; Quinolones; Substance Withdrawal Syndrome; Young Adult

2018